Marinus Pharmaceuticals INC: directors' dealings · United States · SEC (Form 4)

About Marinus Pharmaceuticals INC

Marinus Pharmaceuticals Inc. (ticker MRNS) was a U.S.-listed biopharmaceutical company traded on NASDAQ in the United States. Historically headquartered in Radnor, Pennsylvania, Marinus focused on developing and commercializing innovative therapies for rare seizure disorders, with particular expertise in genetic and pediatric epilepsies. Founded in 2003, the company built its franchise around ganaxolone, a GABA-A receptor modulator, and reached an important milestone in 2022 when the FDA approved ZTALMY (ganaxolone) for seizures associated with CDKL5 deficiency disorder in patients two years of age and older. Operationally, Marinus evolved from a pure development-stage biotech into a commercial-stage company anchored by a single lead product. ZTALMY became its core commercial asset, while the company also explored additional opportunities in severe and rare epilepsies, including status epilepticus, tuberous sclerosis complex, and other orphan pediatric indications. This focus on rare neurological disease gave Marinus a differentiated scientific and regulatory niche, but it also meant that its addressable market was structurally limited and highly dependent on reimbursement dynamics, specialist adoption, and the pace of prescription growth. From a competitive standpoint, Marinus was best understood as a specialty rare-disease player rather than a scaled pharmaceutical platform. Its historical strengths included clinical innovation, deep knowledge of high-need patient populations, and the ability to secure regulatory validation in an orphan indication. At the same time, the company remained highly exposed to commercialization execution, financing conditions, and therapeutic competition. For international investors, it should therefore be viewed as a high-risk biotech name where value creation depended primarily on clinical success and commercial traction rather than broad portfolio diversification. The most important recent development was the completion of Immedica Pharma AB’s acquisition of Marinus on February 11, 2025. Following that transaction, Marinus became a wholly owned subsidiary of Immedica and its shares ceased trading on NASDAQ. Prior to the deal close, the company had also faced Nasdaq listing pressure related to share-price compliance, underscoring how fragile market sentiment had become. For French, Belgian, and Swiss investors, the key takeaway is that Marinus was a U.S. health-care specialist listed on NASDAQ in the United States, now integrated into Immedica’s rare-disease platform.